Alitretinoin (Panretin)

From - A Hematology Oncology Wiki
Jump to navigation Jump to search

Mechanism of action

From the NCI Drug Dictionary: An orally- and topically-active naturally-occurring retinoic acid with antineoplastic, chemopreventive, teratogenic, and embryotoxic activities. Alitretinoin binds to and activates nuclear retinoic acid receptors (RAR) and retinoid X receptors (RXR); these activated receptors act as transcription factors, regulating gene expression that results in the inhibition of cell proliferation, induction of cell differentiation, and apoptosis of both normal cells and tumor cells.

Diseases for which it is used

Patient Drug Information

History of changes in FDA indication

  • 1999-02-02: Initial approval for topical treatment of cutaneous lesions in patients with AIDS-related Kaposi’s sarcoma. (Based on Walmsley et al. 1999 & Bodsworth et al. 2001)

Also known as

  • Code names: ALRT-1057, LGD-1057
  • Brand names: Panretin, Panretyn, Panrexin